Day: September 21, 2021

The Venture Capital Platform Announces A New Investment in Evanesce – A Sustainable Packaging Solutions Company VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) — Billy Goat Brands Ltd. (the “Company” or “Billy Goat”) (CSE: GOAT), a venture capital platform focused on identifying, sponsoring and incubating environmental, social and governance (“ESG”) focused companies in the blue economy, is pleased to provide the following corporate update and investment outlook for Billy Goat’s shareholders, stakeholders and other interested parties. The Company is also pleased to announce its investment in Evanesce Packaging Solutions Inc. (“Evanesce”), which is a sustainable packaging disruptor that is accelerating the adoption of green packaging while re-designing standard disposable food containers. Billy Goat offers investors...

MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence Eichenfield, MD, FAAD, as chair of its Scientific Advisory Board, comprising experts in dermatology and allergic disease from the United States, Canada, Europe, and Asia. Dr Eric Simpson, MD, MCR, was also appointed as a board member. Dr Lawrence Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego​, Distinguished Professor of Dermatology and Pediatrics and Vice Chair of the Department of Dermatology at University of California San Diego School of Medicine​. Dr Eichenfield has served as lead author...

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Sabre Gold Mines Corp. (TSX: SGLD, OTCQB: SGLDF) (“Sabre Gold” or the “Company”) is pleased to announce an updated mineral resource at its 100%-owned Copperstone gold project located in Arizona, United States. Highlights:23% increase in gold ounces in all categories;53% increase in Measured Resources to 196,000 gold ounces at 7.6 g/t;45% increase in Inferred Resources to 212,000 gold ounces at 5.9 g/t;The resource was estimated at a gold price of $1,700 ounce with a modest reduction of 9,700 ounces when calculated at a gold price of $1,600 ounce;Underground mapping and sampling confirm that the mineralized domains occur where previously modelled;Drilling continued to demonstrate continuity in mineralization within mineralized domains and delimited some domain edges where step...

The R&D project with Yissum Research Development Company will contribute to Clearmind’s IP portfolio TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has established a research and development project with Yissum Research Development Company (“Yissum”), the technology transfer company of The Hebrew University of Jerusalem. The collaboration will focus on developing novel, innovative, patentable psychedelics as potential drug candidates to expand Clearmind’s IP portfolio. Yissum is known for its ability to discover, analyze and...

Figure 1Plan View Map of J Zone with Location of New Drill ResultsFigure 2J Zone, Section N15075; View of drill holes TLG-ZJ21-244 and TLG-ZJ21-245TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF) (“Troilus” or the “Company”) reports additional results from its ongoing exploration and infill drill program on its 100%-owned Troilus Gold Project (“Troilus” or the “Project”), which hosts one of the largest undeveloped gold and copper deposits in Quebec, Canada. New results from the J Zone have further confirmed and expanded a parallel zone of mineralization on the western side of the main ore body by up to 50 metres down dip. This new parallel zone of mineralization can be traced over an 850-metre strike length, and is located primarily within the Preliminary...

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced it has been selected to deliver the design and experimentation phase of the Next Generation Human Resources and Pay pilot by the Government of Canada. Ceridian will work with the Government of Canada to co-design and deliver intelligent HR and pay solutions for the federal public service. “With our global leadership in human capital management, complemented by our deep and longstanding commitment to Canada, we are in a unique position to support Canada’s digital-first vision for modern, mobile, and accessible HR and pay processes,” said David Ossip, Chairman and CEO, Ceridian. “We look forward to continuing our work with the Government of Canada, unions, and employees by providing...

Contract to support infrastructure programs that drive sustainable economic growth, expand education, enhance food security, protect the environment, and address health challenges in USAID partner countries EDMONTON, Alberta and NEW YORK and WASHINGTON, Sept. 21, 2021 (GLOBE NEWSWIRE) — TSX, NYSE:STN Stantec, a global leader in sustainable design and engineering, has been selected by the United States Agency for International Development (USAID) to provide global architect-engineer (A/E) services through a five-year, US$800 million multiple-award task order contract. Services under this agreement include planning, design, rehabilitation, and construction supervision for the development of schools, health facilities, and energy, water, sanitation, agriculture, and transportation-related infrastructure. The federal agency leads international...

SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced an update on its CD73 inhibitor program. ORIC recently announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for ORIC-533 to proceed into a first-in-human clinical trial in which ORIC-533 will be tested as a single agent in an undisclosed tumor type not currently known to be under clinical evaluation with any other CD73 inhibitor. ORIC-533 was discovered internally at ORIC, is wholly owned, and is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play...